key: cord-0997928-pmzjjw1c
authors: Goldschmidt, Karen
title: COVID-19 vaccines for children: The essential role of the pediatric nurse
date: 2020-12-11
journal: J Pediatr Nurs
DOI: 10.1016/j.pedn.2020.12.004
sha: 7bf7ddcd65bf01479ee2a76f2c5798efca942464
doc_id: 997928
cord_uid: pmzjjw1c

nan

On January 27, 2020, due to high rates of the COVID-19 virus spread through the U.S. population, a national public health emergency was announced; concurrently, routine vaccination rates began to decrease across all age groups (NFID, 2020) . A decline in routine vaccination rates was due to decreases in primary care office visits, elective procedures, healthcare providers' interactions, and increases in telemedicine visits (HHS, 2020b) . The COVID-19 virus has not only had a direct effect on children through contracting the disease; indirect effects are only beginning to emerge. Research is just starting to surface, demonstrating the detrimental impact that COVID-19 has had on children. Adverse sequela from the virus stems from the effects of minimizing virus spread and quarantine efforts.

Once scientists and engineers have access to a pathogen's genome, using technology, they can identify parts of the virus' Messenger RNA (mRNA); each strand is a potential vaccine (Molteni, 2020) . Before the COVID-19 vaccines, scientists developed genetically engineered vaccines; however, none of them made it to clinical trials due to a lack of financial backing, mainly due to lack of monetary gain for big pharma's involvement. The U.S. government accelerated the timeline and funding for the COVID-19 vaccine through the Operation Warp Speed (OWS) (HHS, 2020a) initiative. The OWS initiative provided ten billion dollars, a timeline, and resources needed to jumpstart vaccine development. The COVID-19 vaccine is a scientific breakthrough in vaccine development. On January 10, 2020, Chinese researchers shared the genetic code of the coronaviruses' ribonucleic acid (RNA) sequence; this opened the door for genetic researchers to begin developing and testing vaccines (Abbasi, 2020) . The technology utilized to create genetically engineered vaccines has the potential for use to treat other viruses and chronic diseases. The three types of COVID-19 vaccines entering the market that have been tested in adult clinical trials include 1) messenger RNA (mRNA) vaccines; 2) vector vaccines, and; 3) protein subunit vaccines (CDC, 2020d). All but one of the vaccines requires two doses that are about 2-3 weeks apart. Additionally, it takes a few weeks for the body to build immunity after the vaccine series. The mRNA vaccines contain genetic material specific to the COVID-19 virus (Abbasi, 2020; CDC, 2020d) . Once the genetic vaccine is administered, the host's cells make the protein antigen that closely mimics the virus. In turn, the human body creates antibodies, T-Cells, and B-lymphocytes, to fight the protein, thus creating memory cells and protection for future exposure to the virus. The newer gene-based, viral vector, DNA, and RNA vaccines use a technique where the genetic instructions of the COVID-19 virus are inserted into a live weekend virus (i.e., adenovirus) (Abbasi, 2020; CDC, 2020d) . Once the vaccine is administered, the J o u r n a l P r e -p r o o f weakened viral vector enters the cells. The human body reacts by creating T-cells and B-lymphocytes, thus creating memory cells and protecting future exposure to the virus. The protein subunit vaccines contain harmless proteins of the COVID-19 virus (Abbasi, 2020; CDC, 2020d) . Once the vaccine is administered, the human body reacts by developing T-cells and antibodies to the COVID-19 virus, creating memory cells and protecting future exposure to the virus.

Children have yet to be included in clinical trials of the COVID-19 vaccine. The AAP (2020b) is calling for children's inclusion in COVID-19 vaccine clinical trials. Thus far, the vaccine trials near the completion stage and awaiting FDA approval only included adult participants. There are four clinical research sites in the U.S. that have been working since May 2020 to test the efficacy and safety of Pfizer Inc. mRNA COVID-19 vaccine in adults (Cincinnati Children's, 2020). Phase three trials began in October 2020, two of the clinical sites began adding children ages 12-17 years old to the trials. Moderna Inc. includes children over 11 years of age in their trials in the coming weeks. The current vaccines took approximately ten months for development, testing, approval, massproduction, and distribution is in process. Children and pregnant women are a vulnerable population, but work must continue to ensure that they also receive a vaccine tested for efficacy and safety (AAP, 2020b).

Researchers must take what is known from the adult COVID-19 vaccine trials and continue to conduct trials that include younger children and pregnant women. Continuing trial phases with smaller groups of children and pregnant women, the vaccine may be approved for these vulnerable groups in a more expeditious time frame to minimize the negative impact that COVID-19 has already had on children's lives. Now maybe a time for pediatric nurses to reimagine outcomes-based research in the settings in which they practice.

There is much that is unknown about the COVID-19 vaccines. To start, the duration that the vaccine protects individuals and if and when a booster will be necessary to maintain immunity is not known. The current recommendation from the CDC (2020b) is that even if a person had COVID-19, they should receive a vaccination; there is not enough information on natural immunity and vaccine-induced immunity. It is unknown how many people will choose the COVID-19 vaccination and or if there will be requirements for vaccination by employers or school environments. Also, the cost of the vaccine for governments and individuals is unknown (Roush, 2020) . Lastly, there is no evidence on when to vaccinate children or pregnant women and the effects of the vaccine on this population. There is already much hype in the media, creating anxiety for adults about taking the COVID-19 vaccine (Tyson, Johnson & Funk, 2020) . Adults can often be overheard J o u r n a l P r e -p r o o f asking one another, "Will you take the vaccine?" Generally, there are public concerns that scientists developed the vaccine too quickly and that there is not enough information to know if it works. To achieve herd immunity, 55%-82% of the population needs to be immune from the COVD-19 virus, either from natural or vaccination or prior infection (Roush, 2020) . Public acceptance of COVID-19 vaccination is crucial. There are racial disparities in adults' likeliness to get a vaccination. A Pew Foundation poll found "Black adults are much less likely to say they would get a vaccine than other Americans: Just 32% of Black adults say they would definitely or probably get a COVID-19 vaccine, compared with 52% of White adults, 56% of Hispanics and nearly threequarters (72%) of Asian Americans. (Asian adults were interviewed in English only.)" (Tyson et al., para.6.) If parents have fears about taking the COVID-19 vaccine, will they refuse to have their children vaccinated?

The primary action that pediatric nurses can take is to educate themselves about the COVID-19 vaccine with evidence-based information. Pediatric nurses are accustomed to approaching parents and patients with evidence-based vaccine information and allying their fears. Nurses realize that parents' anxieties stem from inaccurate information shared by well-meaning friends and family members or erroneous information posted on the Intranet and social media sites. The measles, mumps, and rubella (MMR) vaccine is one example of a vaccine where the Intranet information has created confusion and anxiety for parents. Pediatric nurses are the experts at administering vaccines to children. When administering a vaccine, nurses consider the child's age and developmental level, the caregiver's anxiety, and the number of vaccines due to be distributed (Stevens & Marvicsin, 2016) . Pediatric nurses instruct caregivers on how to hold their child's position steady and comfort them at the same time. Pediatric nurses interact with children of all ages. They can continue to advocate for them by reviewing vaccination histories wherever and whenever they interact with them and their families in the healthcare or school setting. Noting missed vaccinations, helping caregivers create a vaccine "catch-up" schedule if a child is off track, and offering guidance to vaccination services for Medicaid and uninsured families will help maintain the child's wellbeing and minimize hospitalizations. The Advisory Committee on Immunization Practices (ACIP). Workgroup released their initial multi-phased plan for vaccine allocation on December 1, 2020. If the vaccine trials demonstrate that COVID-19 vaccines are safe and effective, the FDA will approve the vaccine, and it will be available for distribution in a matter of days. The government will rely on healthcare workers to educate the public about the efficacy and safety of the COVID-19 vaccine (CDC, 2020e). Many nurses will be recipients of the first phase of mRNA vaccine administration. Just as other vaccines are required of all healthcare workers to work in a hospital, it will be interesting to see if institutional' policies for J o u r n a l P r e -p r o o f mandatory COVID-19 vaccinations for all healthcare workers follow. Pediatric nurses could be role models for parents and children for whom they care by being vaccinated. Summary

The COVID-19 pandemic has affected both children and their families in more ways than is known and will impact many years to come. The promise of new genetically engineered vaccines provides hope for an avenue toward a new normal. Nurses' role in vaccination is crucial. Pediatric nurses are experts in administering childhood vaccinations. Nurses can be advocates by increasing awareness of the need for clinical vaccination trials for children and pregnant mothers. Pediatric nurses' can promote children's wellbeing by administering vaccines, educating patients and families, and leading campaigns to increase awareness for COVID-19 and routine childhood vaccinations.

COVID-19 and mRNA vaccines-First large test for new approach

December 2.). ACIP recommends healthcare personnel and LTCF residents for phase 1a of COVID-19 vaccination program; IAC summarizes two ACIP meetings held on

AAP: HHS action on pharmacy vaccination "misguided

AAP: Include children in COVID-19 vaccine trials

Health Department-Reported cases of Multisystem Inflammatory Syndrome in children (MIS-C) in the United States

10 things Healthcare professionals need to know about U.S. COVID-19 vaccination plans

COVID-19: Impact for pediatric research, evidence-based practice and quality processes and projects

Why it's a big deal if the first Covid vaccine is 'genetic

The race to develop a COVID-19 vaccine

Evidence-based recommendations for reducing pediatric distress during vaccination

Public now divided over whether to get COVID-19 Vaccine

Fact sheet: Explaining Operation Warp Speed